| Abstract: | Objective To investigate the status of urinary tract infections and drug susceptibility of Streptococcus agalactiae (GBS) in patients with systemic lupus erythematosus (SLE), and provide evidence for clinical treatment. Methods A retrospective analysis of secondary urinary tract infections and drug susceptibility in patients with SLE from April 2011 to November 2018 in Xinjiang Uygur Autonomous Region People’s Hospital. Results There were 78 positive cases of urinary cultures in 153 SLE patients. Among the 45 cases of Gram-negative bacteria, 18 cases were Escherichia coli, nine cases were Klebsiella pneumoniae, six cases were Proteus mirabilis, and four cases were Gardnerella vaginalis. Four cases were Enterobacter cloacae, and four cases were Pseudomonas aeruginosa. Among the 33 cases of Gram-positive bacteria, 16 cases were GBS, six cases were Enterococcus faecalis, four cases were Staphylococcus, three cases were Enterococcus faecium, three cases were yeast, and one case of saliva chain cocci. Drug susceptibility results showed that 16 strains of GBS showed resistance to levofloxacin (31.25%), erythromycin (68.75%), tetracycline (37.5%), and clindamycin (81.5%). Intermediate strains to levofloxacin were 6.25%; The sensitivity rates to linezolid, penicillin, vancomycin, meropenem, ampicillin, and ceftriaxone were all 100%. Conclusion GBS caused by urinary tract infections in SLE patients should be paid attention to, and clinicians need to choose antibiotics reasonably based on the results of drug |
